Institut De Formulation DES Vaccins (Ch) SA
Plan-les-Ouates, GE Doing business as Vaccine Formulation Institute (Ch) LTD
- UEI
- N773KSZMJA78
- CAGE
- SMVP9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- Rue du Champ-Blanchod 4, 1228 Plan-les-Ouates, Switzerland
- Website
- vaccineformulationinstitute.org
- Founded
- 2011
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- SIC code
- 99 Non-Classifiable Establishments
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Vaccine adjuvant discovery program | National Institute of Allergy and Infectious Diseases | $1,563,776 | |
| Advanced development of LQ a liposome-based saponin-containing adjuvant for use in pansarbecovirus vaccines | National Institute of Allergy and Infectious Diseases | $8,193,365 |
About Institut De Formulation DES Vaccins (Ch) SA
Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, is a non-profit limited liability company registered to receive awards from the U.S. federal government. Specializing in vaccine formulation and adjuvant development, the organization provides expertise in the advanced development of vaccine components and delivery systems. The institute focuses on improving vaccine efficacy and safety through innovative formulation techniques and the discovery of novel adjuvants. As a research-oriented entity, it plays a crucial role in enhancing the effectiveness of vaccines by developing and optimizing adjuvants, which are substances added to vaccines to boost the immune response.
The institute has been awarded two significant federal contracts by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The first contract, valued at $9,189,961.00, is for the Vaccine Adjuvant Discovery Program, which aims to identify and characterize novel, effective, and safe vaccine adjuvants through a multi-step research process. This five-year definitive contract, running from September 2024 to September 2029, demonstrates the institute's capability in conducting complex, long-term research projects in vaccine development. The second contract, worth $4,937,118.00, focuses on the advanced development of a liposome-based saponin-containing adjuvant for use in pan-sarbecovirus vaccines. This fixed-price definitive contract, awarded in September 2023 with completion scheduled for September 2028, showcases the institute's expertise in developing specific adjuvant technologies for emerging viral threats. Both contracts were awarded without set-aside designations, indicating the institute's competitive standing in the field.
In addition to its contract work, Institut De Formulation DES Vaccins (Ch) SA has received a federal grant sub-award as part of a project led by the University of California, San Diego. This sub-award, under grant R01AI173689, involves the institute in a collaborative effort to identify the most effective adjuvants for leading Group A Streptococcal vaccine antigens in preclinical mouse and nonhuman primate models. The institute's role includes manufacturing and sourcing adjuvants, establishing antigen integrity methods, conducting stability studies on formulations, and providing lab-scale quantities of compatible adjuvants to project partners. This work, scheduled from February 2023 to January 2028, demonstrates the institute's capability in supporting comprehensive vaccine development efforts through specialized formulation and stability testing services. The involvement in this grant-funded research underscores the institute's versatility and importance in the field of vaccine development and adjuvant discovery, particularly in supporting academic research initiatives.
Quick answers
What is Institut De Formulation DES Vaccins (Ch) SA's UEI?
Institut De Formulation DES Vaccins (Ch) SA's Unique Entity ID (UEI) in SAM.gov is N773KSZMJA78.
What is Institut De Formulation DES Vaccins (Ch) SA's CAGE code?
Institut De Formulation DES Vaccins (Ch) SA's CAGE code is SMVP9.
What is Institut De Formulation DES Vaccins (Ch) SA's primary NAICS code?
Institut De Formulation DES Vaccins (Ch) SA's primary NAICS code is 541990 (All Other Professional, Scientific, and Technical Services).
Where is Institut De Formulation DES Vaccins (Ch) SA located?
Institut De Formulation DES Vaccins (Ch) SA's physical address in SAM.gov is Rue du Champ-Blanchod 4, 1228 Plan-les-Ouates, Switzerland.
Is Institut De Formulation DES Vaccins (Ch) SA registered in SAM.gov?
Yes. Institut De Formulation DES Vaccins (Ch) SA's SAM.gov registration is active through July 28, 2027.
What is Institut De Formulation DES Vaccins (Ch) SA's most recent federal award?
Institut De Formulation DES Vaccins (Ch) SA's most recent federal contract award is Vaccine adjuvant discovery program (75N93024C00021), from National Institute of Allergy and Infectious Diseases, on September 30, 2024.
On GovTribe
See Institut De Formulation DES Vaccins (Ch) SA's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors